JPRN-jRCT2051200126已完成1 期
A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose, and Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-723595 in Healthy Adult Participants (Part 1); and A Phase 1, Randomized, Double-Blind, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-723595 and A Drug-Drug Interaction Study with the CYP3A Substrate, Midazolam, in Healthy Adult Participants (Part 2) - A Phase 1, Single-Dose, Multiple-Dose, Food Effect, and Midazolam Drug-Drug Interaction Study of S-723595
agata Tsutae0 个研究点目标入组 94 人开始时间: 2021年1月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •Japanese or Caucasian male >= 20 to =< 55 years of age, at the time of signing the informed consent form (ICF).
排除标准
- •Considered by the investigator or subinvestigator (suitably qualified) to be ineligible for the study due to a history of or current condition of significant metabolic or endocrine, hepatic, renal, hematological, cardiovascular, gastrointestinal or neurological disorders that are considered by the investigator to constitute a safety risk upon the study drug administration or to interfere with the interpretation of data.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and the processing of GDC-0829 by the body in healthy participantsHealthy volunteersISRCTN18049481F. Hoffmann-La Roche Ltd104
已完成
1 期
PK and PD study of G-CSF (BioGenomics Ltd) vs Neupogen® in healthy volunteersCTRI/2017/10/010040BioGenomics Ltd59
已完成
1 期
A study to assess the safety and processing by the body of GDC-5780 in healthy participantsHealthy volunteersISRCTN15259645F. Hoffmann-La Roche Ltd56
进行中（未招募）
1 期
A study to evaluate safety and pharmacokinetics (processing by the body) of single ascending doses of GDC-5780 in healthy participantsISRCTN16073754Roche (United States)56
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CH-4051 in healthy male subjects10003816rheumatoid arthritisNL-OMON32763Chelsea Therapeutics, Inc.56